A Scoring Algorithm for Deriving Utility Values from the Neuro-QoL for Patients with Multiple Sclerosis.

Louis S MatzaGlenn PhillipsBarry D DewittKatie D StewartDavid CellaDavid FeenyJanel HanmerDeborah M MillerDennis A Revicki

Published in: Medical decision making : an international journal of the Society for Medical Decision Making (2020)

With the NQU, utilities can be derived from any MS treatment group, subgroup, or patient sample who completes items from 6 Neuro-QoL domains. Because the Neuro-QoL is frequently used with MS patients, the NQU greatly expands the options for quantifying outcomes in cost-utility analyses conducted to inform allocation of resources for MS treatment.

Keyphrases

mass spectrometry
multiple sclerosis
ms ms
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
machine learning
randomized controlled trial
type diabetes
case report
deep learning
skeletal muscle
insulin resistance
patient reported outcomes